NCT05462262View on ClinicalTrials.gov

Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population

NAEnrolling by invitationINTERVENTIONAL
Enrollment

2,900

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

October 31, 2029

Conditions
Coronary Artery Disease Progression
Interventions
DRUG

Intensive lipid-lowering control

The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.

DRUG

Moderate-intensity lipid-lowering control

The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.

Trial Locations (1)

Unknown

Fuwai Hospital, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER